The latest price target for DiaMedica Therapeutics (NASDAQ:DMAC) was reported by HC Wainwright & Co. on October 10, 2024. The analyst firm set a price target for $7.00 expecting DMAC to rise to within 12 months (a possible 74.56% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for DiaMedica Therapeutics (NASDAQ:DMAC) was provided by HC Wainwright & Co., and DiaMedica Therapeutics reiterated their buy rating.

The last upgrade for DiaMedica Therapeutics Inc happened on June 22, 2023 when Oppenheimer raised their price target to $7. Oppenheimer previously had a perform for DiaMedica Therapeutics Inc.

The last downgrade for DiaMedica Therapeutics Inc happened on July 7, 2022 when Oppenheimer changed their price target from N/A to N/A for DiaMedica Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DiaMedica Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DiaMedica Therapeutics was filed on October 10, 2024 so you should expect the next rating to be made available sometime around October 10, 2025.

While ratings are subjective and will change, the latest DiaMedica Therapeutics (DMAC) rating was a reiterated with a price target of $7.00 to $7.00. The current price DiaMedica Therapeutics (DMAC) is trading at is $4.01, which is out of the analyst’s predicted range.